These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35987868)

  • 1. Commentary: The search for a chemotherapy-free immunotherapy regimen in resectable non-small cell lung cancer: The unmet need.
    Lee JM
    J Thorac Cardiovasc Surg; 2023 Jan; 165(1):335-336. PubMed ID: 35987868
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant or neoadjuvant therapeutic strategy for resectable non-small cell lung cancer.
    Hayashi R
    Respir Investig; 2023 Mar; 61(2):133-134. PubMed ID: 36634545
    [No Abstract]   [Full Text] [Related]  

  • 3. Turning the tides on the perioperative care of resectable lung cancer.
    Seitlinger J; Spicer JD
    J Thorac Cardiovasc Surg; 2023 Nov; 166(5):1340-1346. PubMed ID: 37115120
    [No Abstract]   [Full Text] [Related]  

  • 4. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
    Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
    Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer.
    Shu CA; Cascone T
    J Clin Oncol; 2021 Sep; 39(26):2855-2858. PubMed ID: 34339287
    [No Abstract]   [Full Text] [Related]  

  • 6. Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer.
    Erwin P; Donington J
    J Thorac Cardiovasc Surg; 2023 Jun; 165(6):1949-1953. PubMed ID: 36528434
    [No Abstract]   [Full Text] [Related]  

  • 7. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
    Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
    Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative therapy for locoregional nonsmall-cell lung cancer.
    Takita H
    J Surg Oncol; 1996 May; 62(1):65-74. PubMed ID: 8618405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early-stage non-small-cell lung cancer: adjuvant versus neoadjuvant chemotherapy.
    Belani CP
    Clin Lung Cancer; 2003 Jul; 5(1):11-2. PubMed ID: 14596696
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
    Nagasaka M; Gadgeel SM
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):63-70. PubMed ID: 29168933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. There and back again: An immunotherapy tale.
    Guo Y; Krupnick AS
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract]   [Full Text] [Related]  

  • 12. Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study.
    Ratto GB; Costa R; Maineri P; Alloisio A; Piras MT; D'Agostino A; Tripodi G; Rivabella L; Dozin B; Bruzzi P; Melioli G
    Int J Immunopathol Pharmacol; 2011; 24(4):1005-16. PubMed ID: 22230406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neoadjuvant chemotherapy in non-small cell lung cancer: current state and future].
    Mellas N; Elmesbahi O; Masbah O; Errihani H
    Bull Cancer; 2010 Feb; 97(2):211-23. PubMed ID: 20051349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When immunotherapy meets surgery in non-small cell lung cancer.
    Herbst RS; Wang M; Chen L
    Cancer Cell; 2022 Jun; 40(6):603-605. PubMed ID: 35660136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neo-adjuvant chemotherapy in non-small cell lung cancer (NSCLC).
    Santo A; Genestreti G; Sava T; Manno P; Terzi A; Molino AM; Cetto GL
    Ann Oncol; 2006 May; 17 Suppl 5():v55-61. PubMed ID: 16807464
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy for resectable non-small cell lung cancer.
    Finkelstein EJ; Urschel JD; Takita H
    J Exp Clin Cancer Res; 1997 Dec; 16(4):437-9. PubMed ID: 9505221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
    Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
    J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in immune neoadjuvant/adjuvant therapy-related adverse events of non-small cell lung cancer.
    Zhao Q; Liu C; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Jun; 18(3):171-176. PubMed ID: 32573077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
    J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
    Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.